Corixa Corporation

Alderbio Holdings LLC

H. Lundbeck A/s

Alder Biopharmaceuticals, Inc.

Patricia Dianne McNeill

John A Latham

Leon F Garcia-Martinez

Danielle Mitchell

Benjamin H Dutzar

Brian Robert Kovacevich

Katie Olson Anderson

Jens J Billgren

Raymond L Houghton

Ethan Wayne Ojala

Steven G Reed

Michael J Lodes

Pei Fan

Erica Ann Stewart

Nicole M Janson

Maria-Cristina Loomis

Yasir A W Skeiky

Aijun Wang

Andrew Lawrence Feldhaus

Alexander Gaiger

Davin C Dillon

Gary R Fanger

Daniel S Allison

Michael D Kalos

Robert A Henderson

Samuel X Li

Corinne C Akatsuka

Gary Lesnicki

Jeffrey T L Smith

Michelle Scalley-Kim

Charlie Karasek

Jenny Mulligan

Mark Young

Franz Hartner

Yasir A Skeiky

Tongtong Wang

Nancy Ann Hosken

Chaitanya S Bangur

Liqun Fan

Betty Yu-Ching Chang

Jennifer L Mitcham

Darrick Carter

Jiangchun Xu

Thomas S Vedvick

Marc W Retter

Susan L Harlocker

Yuqiu Jiang

John A Stolk

Craig H Day

Paul R Sleath

William T Hepler

Carlota Vinals Y De Bassols

Teresa M Foy

John M Smith

Paul Algate

Jane Mannion

Lauren Carter

Yoshihiro Watanabe

Mehmet Inan

Madeleine Joy Meagher

Jonathan David Clapper

Nadia Ordonez

Nomalie Jaya

John Hural

Katie Olson

Leon F Garcia-martinez

Heather Secrist

Neil Fanger

Ta Deng

Pei Qi

Mary J Homer

Dan Scott Allison

Paul A Algate

Jeffrey TL Smith

Gary L Lesnicki

Danielle M Mitchell

Danielle Marie Mitchell

The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the V, Vand/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as CAH, FGD, Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders, depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.

Humanized anti-ACTH antibodies and use thereof

A feedback control mechanism for a fermentation of yeast cells to make recombinant proteins uses a respiratory quotient measurement which adjusts the levels of oxygenation and/or fermentable sugar feed. The feedback control mechanism permits well controlled cultures that produce good amounts of product while avoiding toxic accumulation of ethanol. Additionally, recombinant proteins so produced have excellent qualitative properties, such as excellent homogeneity and proper inter-subunit assembly.

Fermentation process for antibody production

Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as

[object Object]

Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as

Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as

High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Anti-CGRP compositions and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

Anti-NGF compositions and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.

Anti-PCSK9 antibodies and use thereof

Growing community of inventors

Federal Way, WA, United States of America

Patricia Dianne McNeill